文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

SiMPl-GS:通过用于下一代生物制药生产的合成选择标记推进细胞系开发。

SiMPl-GS: Advancing Cell Line Development via Synthetic Selection Marker for Next-Generation Biopharmaceutical Production.

机构信息

Department of Biological Sciences, KAIST, Daejeon, 34141, Republic of Korea.

Biotherapeutics Translational Research Center, KRIBB, Daejeon, 34113, Republic of Korea.

出版信息

Adv Sci (Weinh). 2024 Oct;11(38):e2405593. doi: 10.1002/advs.202405593. Epub 2024 Aug 6.


DOI:10.1002/advs.202405593
PMID:39105414
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11481413/
Abstract

Rapid and efficient cell line development (CLD) process is essential to expedite therapeutic protein development. However, the performance of widely used glutamine-based selection systems is limited by low selection efficiency, stringency, and the inability to select multiple genes. Therefore, an AND-gate synthetic selection system is rationally designed using split intein-mediated protein ligation of glutamine synthetase (GS) (SiMPl-GS). Split sites of the GS are selected using a computational approach and validated with GS-knockout Chinese hamster ovary cells for their potential to enable cell survival in a glutamine-free medium. In CLD, SiMPl-GS outperforms the wild-type GS by selectively enriching high producers. Unlike wild-type GS, SiMPl-GS results in cell pools in which most cells produce high levels of therapeutic proteins. Harnessing orthogonal split intein pairs further enables the selection of four plasmids with a single selection, streamlining multispecific antibody-producing CLD. Taken together, SiMPl-GS is a simple yet effective means to expedite CLD for therapeutic protein production.

摘要

快速高效的细胞系开发(CLD)过程对于加速治疗性蛋白的开发至关重要。然而,广泛使用的基于谷氨酰胺的选择系统的性能受到低选择效率、严格性以及无法选择多个基因的限制。因此,使用分裂内含子介导的谷氨酰胺合成酶(GS)的蛋白连接(SiMPl-GS)合理设计了 AND 门合成选择系统。GS 的分裂位点使用计算方法选择,并通过 GS 敲除中国仓鼠卵巢细胞进行验证,以评估其在无谷氨酰胺培养基中促进细胞存活的潜力。在 CLD 中,SiMPl-GS 通过选择性富集高产细胞,优于野生型 GS。与野生型 GS 不同,SiMPl-GS 导致大多数细胞产生高水平治疗蛋白的细胞池。利用正交分裂内含子对进一步实现了使用单个选择来选择四个质粒,简化了多特异性抗体产生的 CLD。总之,SiMPl-GS 是一种简单而有效的方法,可以加速治疗性蛋白生产的 CLD。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/c9b5b608560f/ADVS-11-2405593-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/9461b68a4e2a/ADVS-11-2405593-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/5167570638f3/ADVS-11-2405593-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/9e9d20f26cee/ADVS-11-2405593-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/e268b215cc28/ADVS-11-2405593-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/12cb02db5050/ADVS-11-2405593-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/e0b2fff04078/ADVS-11-2405593-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/c9b5b608560f/ADVS-11-2405593-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/9461b68a4e2a/ADVS-11-2405593-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/5167570638f3/ADVS-11-2405593-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/9e9d20f26cee/ADVS-11-2405593-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/e268b215cc28/ADVS-11-2405593-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/12cb02db5050/ADVS-11-2405593-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/e0b2fff04078/ADVS-11-2405593-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49c6/11481413/c9b5b608560f/ADVS-11-2405593-g007.jpg

相似文献

[1]
SiMPl-GS: Advancing Cell Line Development via Synthetic Selection Marker for Next-Generation Biopharmaceutical Production.

Adv Sci (Weinh). 2024-10

[2]
Attenuated glutamine synthetase as a selection marker in CHO cells to efficiently isolate highly productive stable cells for the production of antibodies and other biologics.

MAbs. 2019-6-4

[3]
Development of a highly-efficient CHO cell line generation system with engineered SV40E promoter.

J Biotechnol. 2013-8-29

[4]
Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells.

Biotechnol Bioeng. 2011-11-21

[5]
Enhancing CHO cell productivity through a dual selection system using Aspg and Gs in glutamine free medium.

Biotechnol Bioeng. 2023-4

[6]
Glutamine synthetase (GS) knockout (KO) using CRISPR/Cpf1 diversely enhances selection efficiency of CHO cells expressing therapeutic antibodies.

Sci Rep. 2023-6-28

[7]
Attenuation of glutamine synthetase selection marker improves product titer and reduces glutamine overflow in Chinese hamster ovary cells.

Biotechnol Bioeng. 2022-7

[8]
Improvement of the efficiency and quality in developing a new CHO host cell line.

Biotechnol Prog. 2021-9

[9]
Optimization of cell line development in the GS-CHO expression system using a high-throughput, single cell-based clone selection system.

J Biosci Bioeng. 2015-9

[10]
Reduction of ammonia and lactate through the coupling of glutamine synthetase selection and downregulation of lactate dehydrogenase-A in CHO cells.

Appl Microbiol Biotechnol. 2017-2

本文引用的文献

[1]
Glutamine regulates the cellular proliferation and cell cycle progression by modulating the mTOR mediated protein levels of β-TrCP.

Cell Cycle. 2023-9

[2]
Mitigating transcriptional bottleneck using a constitutively active transcription factor, VP16-CREB, in mammalian cells.

Metab Eng. 2023-11

[3]
Glutamine synthetase (GS) knockout (KO) using CRISPR/Cpf1 diversely enhances selection efficiency of CHO cells expressing therapeutic antibodies.

Sci Rep. 2023-6-28

[4]
Effects of the COVID-19 pandemic: new approaches for accelerated delivery of gene to first-in-human CMC data for recombinant proteins.

MAbs. 2023

[5]
Weak promoters to drive selection marker expression: Improvement of cell line development process for therapeutic protein production in CHO-K1 cells.

J Biotechnol. 2023-6-10

[6]
Targeting glutamine metabolism as a therapeutic strategy for cancer.

Exp Mol Med. 2023-4

[7]
A CHO stable pool production platform for rapid clinical development of trimeric SARS-CoV-2 spike subunit vaccine antigens.

Biotechnol Bioeng. 2023-7

[8]
Enhancing CHO cell productivity through a dual selection system using Aspg and Gs in glutamine free medium.

Biotechnol Bioeng. 2023-4

[9]
Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry.

Biotechnol Prog. 2023-3

[10]
Novel Split Intein-Mediated Enzymatic Channeling Accelerates the Multimeric Bioconversion Pathway of Ginsenoside.

ACS Synth Biol. 2022-10-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索